SMU-B

• Description :

  SMU-B is the orally active inhibitor for ALK (IC50c-ros oncogene 1 (ROS1), c-MET (IC50=1.87 nM) and AXL (IC50=28.9 nM) . SMU-B inhibits the proliferation of MKN45, H1993 and H441 with IC50s of 0.02 μM, 1.58 μM and 2.82 μM, respectively. SMU-B exhibits antitumor efficacy in mouse models[1][2].

• CAS Number :

  [1253286-90-6]

• UNSPSC :

  12352005

• Target :

  Anaplastic lymphoma kinase (ALK) ; c-Met/HGFR; ROS Kinase; TAM Receptor

• Type :

  Reference compound

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/smu-b.html

• Smiles :

  O=C1NC2=C(C=CC(C3=CC(O[C@@H](C4=C(Cl)C=CC(F)=C4Cl)C)=C(N)N=C3)=C2)C15CCN(C)CC5

• Molecular Formula :

  C26H25Cl2FN4O2

• Molecular Weight :

  515.41

• References & Citations :

  [1]Tian Y, et al., Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK. J Chem Inf Model. 2017 Apr 24;57 (4) :977-987.|[2]Li J, et al., Aminopyridyl/Pyrazinyl Spiro[indoline-3,4'-piperidine]-2-ones As Highly Selective and Efficacious c-Met/ALK Inhibitors. ACS Med Chem Lett. 2013 Jul 12;4 (8) :806-10.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported